Royal Papworth Hospital

PlaqueTec recruits first ten patients in BIOPATTERN trial

Retrieved on: 
Wednesday, November 29, 2023
Stem Cells, Medical Supplies, Practice Management, FDA, Physical Therapy, Diabetes, Managed Care, General Health, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Hospitals, Health Technology, Biometrics, Genetics, Fitness & Nutrition, Cardiology, Biotechnology, Health, Safety, Mallinckrodt, Royal Bournemouth Hospital, MHRA, Disease, World Heart Federation, Risk, Protein, CAD, Patient, Medicine, Research fellow, Death, NHS, Bristol Royal Infirmary, LBS, Royal Papworth Hospital, Coronary artery disease, Harvard Medical School, CVD, Health care, Liquid biopsy, JACC, Pharmaceutical industry, Medical imaging, Medical device

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Key Points: 
  • PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
  • The BIOPATTERN trial will use PlaqueTec’s proprietary blood sampling device, the Liquid Biopsy System™ (LBS), to collect samples at multiple sites along a patient’s diseased coronary artery.
  • Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples.
  • The trial aims to recruit 300 patients with established CAD who have been scheduled for a coronary angiogram.

CMR Surgical surpasses 15,000 surgical procedures on Versius® globally as it raises $165 million to support continued growth

Retrieved on: 
Wednesday, September 20, 2023
SoftBank Vision Fund, CE, Royal college, Enterprise, Surgeon, Accreditation, Journal of Minimal Access Surgery, Gleneagles Hospital, Lung lobectomy, Royal, Tencent, Innovation, MAS, Royal Papworth Hospital NHS Foundation Trust, Sindh Institute of Urology & Transplantation, Hospital, Patient, Royal Papworth Hospital, SIUT, Hernia, Growth, CMR, CMR Surgical, LGT, News, BST, Dentistry

The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.

Key Points: 
  • The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.
  • CMR Surgical (CMR or ‘the Company’) – the global surgical robotics business – has today announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.
  • The surgical cases span more than 130 complex and benign procedure types including colectomies, hernia repairs, hysterectomies, sacrocolpopexies, and lobectomies across seven surgical specialties.
  • CMR’s vision is to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place globally.

CMR Surgical surpasses 15,000 surgical procedures on Versius® globally as it raises $165 million to support continued growth

Retrieved on: 
Wednesday, September 20, 2023
SoftBank Vision Fund, CE, Royal college, Enterprise, Surgeon, Accreditation, Journal of Minimal Access Surgery, Gleneagles Hospital, Lung lobectomy, Royal, Tencent, Innovation, MAS, Royal Papworth Hospital NHS Foundation Trust, Sindh Institute of Urology & Transplantation, Hospital, Patient, Royal Papworth Hospital, SIUT, Hernia, Growth, CMR, CMR Surgical, LGT, News, BST, Dentistry

The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.

Key Points: 
  • The company has recently closed an upsized $165 million (£133 million) fundraising to support continued product innovation and commercial growth in existing and key new markets around the world.
  • CMR Surgical (CMR or ‘the Company’) – the global surgical robotics business – has today announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.
  • The surgical cases span more than 130 complex and benign procedure types including colectomies, hernia repairs, hysterectomies, sacrocolpopexies, and lobectomies across seven surgical specialties.
  • CMR’s vision is to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place globally.

Shockwave Medical Appoints Nick West as Associate Chief Medical Officer

Retrieved on: 
Tuesday, September 12, 2023
Green Lane Hospital, Plaque, FRCP, University, Shock wave, Charing Cross Hospital Medical School, UCLA School of Nursing, Trinity Hall, University of Cambridge, FACC, Cardiovascular disease, Medicine, CMO, Associate, IVL, Congress, John Radcliffe Hospital, Royal Papworth Hospital NHS Foundation Trust, Divisional patent application, European Innovation Council, Cardiology, Royal Papworth Hospital, European Society of Cardiology, FESC, Nursing, Medical device, MD

SANTA CLARA, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the role of Associate Chief Medical Officer.

Key Points: 
  • SANTA CLARA, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the role of Associate Chief Medical Officer.
  • Dr. West will report to Keith Dawkins, MD, Chief Medical Officer, and will be based in Santa Clara, with plans to succeed Dr. Dawkins as CMO in mid-2024.
  • West brings to Shockwave a wealth of expertise in the interventional cardiology space,” said Dr. Dawkins.
  • He is a founding member and Chief Medical Officer of the Cambridge-based vulnerable plaque startup, PlaqueTec Ltd, and sits on the Innovation Council of the UCLA School of Biodesign.

Dedalus Expands Work with AWS as a Strategic Cloud Provider to Transform the Digital Healthcare Ecosystem Globally

Retrieved on: 
Wednesday, December 14, 2022
Maintenance, Diagnosis, Hospital, EHR, Life, Ecosystem, Software, International Public Sector Accounting Standards, Acceleration, Carbon footprint, Digital Connectivity, HCIS, Enterprise imaging, Patient, Amazon Web Services, Elasticity, Laika (EHR testing framework), Digital, Enterprise, Dedalus, Royal Papworth Hospital NHS Foundation Trust, Financial management, FHIR, Health care, Association of Independent Healthcare Organisations, Face, Fast Healthcare Interoperability Resources, Health information management, AWS, Royal Papworth Hospital, Pressure, Organization, Medical device, Medicine, Medical imaging

"We are finally seeing an acceleration in the healthcare community embracing a digital transformation," said Andrea Fiumicelli, CEO of Dedalus Group.

Key Points: 
  • "We are finally seeing an acceleration in the healthcare community embracing a digital transformation," said Andrea Fiumicelli, CEO of Dedalus Group.
  • With Dedalus on AWS, Dedalus will offer global deployments across its expansive portfolio, including:
    Electronic health record (EHR) products powered by our digital platforms such as Digital Connect 4 Healthcare (DC4H),which run on AWS utilizing containers and microservices.
  • "Together, Dedalus and AWS will change what's possible for healthcare organizations, helping them to speed up innovation while improving operational and clinical processes.
  • Dedalus supports the whole continuum of care, offering open standards-based solutions serving each actor of the Healthcare Ecosystem to provide better care in a healthier planet.

 GigXR HoloScenarios Named to TIME’s List of the Best Inventions of 2022; Recognizes Holographic Patient Simulation as Life-Changing Innovation

Retrieved on: 
Thursday, November 10, 2022
Technology, Training, Communications, Health Technology, Defense, Artificial Intelligence, Government Technology, Research, Media, Hospitals, University, Education, Health, Practice Management, Apps, Applications, General Health, Audio, Video, Science, Other Technology, Telecommunications, Telemedicine, Virtual Medicine, Software, Publishing, Cambridge Biomedical Campus, AstraZeneca, Hospital, Carbon, Gig, Cambridge University Hospitals NHS Foundation Trust, Anesthesiology, 3D, TIME, Extended reality, Partnership, Communication, Education, Health, Catalog, Department, NIHR, CBC, Technology, Smartphone, Invention, Internet access, Department of Defense Serum Repository, XR, Royal Papworth Hospital, CUH, Cambridge University Health Partners, University, Trauma, Atmosphere, Solution, CA, Rosie Hospital, Asthma, Consultant, NHS, Anaphylaxis, Pulmonary embolism, Michigan Medicine, Patient, Judgement, Heart, CEO, Medicine, Medical device, Neuroscience, Campus

GigXR, Inc. , a global provider of holographic healthcare training, announced today that its mixed reality patient training application, HoloScenarios, has been awarded TIMES 2022 Best Inventions .

Key Points: 
  • GigXR, Inc. , a global provider of holographic healthcare training, announced today that its mixed reality patient training application, HoloScenarios, has been awarded TIMES 2022 Best Inventions .
  • To ensure medical integrity and realism of HoloScenarios, GigXR partners with healthcare subject matter experts to inform and guide the creation of the holographic simulations.
  • We couldnt be more honored to share TIMES 2022 Best Inventions Award with the team and technologists at GigXR.
  • To see the full list of TIMEs List of the Best Inventions of 2022, visit time.com/best-inventions-2022 .

Inivata and Collaborators Publish Clinical Validation Data for RaDaR™ Assay in Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, March 17, 2022
MRD, Recurrence, D, PPV, Annals of Oncology, Circulating tumor DNA, Technology, University, US, Patient, Cancer Research UK, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Neoplasm, NeoGenomics, Liquid biopsy, Lung cancer, LUCID, Triangle Park (Quezon City), Radar, NASDAQ, CLIA, Research Triangle Park, Cancer research, CAP, Research, Lung, NSCLC, Royal Papworth Hospital, Biotechnology, Cambridge Institute for Sustainability Leadership, Hazard, Laboratory, Medical imaging, Pharmaceutical industry

Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2022 -- Inivata, a leader in liquid biopsy, today announced the publication of new data in support of its RaDaR™ liquid biopsy test in patients with early-stage non-small cell lung cancer (NSCLC). The data from the LUng cancer CIrculating tumor Dna (LUCID) study have been published in the Annals of Oncology. The study was in collaboration with Cancer Research UK Cambridge Institute, University of Cambridge, Royal Papworth Hospital and Cambridge University Hospital.

Key Points: 
  • The data from the LUng cancer CIrculating tumor Dna (LUCID) study have been published in the Annals of Oncology .
  • The study was in collaboration with Cancer Research UK Cambridge Institute, University of Cambridge, Royal Papworth Hospital and Cambridge University Hospital.
  • The study found that the presence of detectable ctDNA after treatment with curative intent was highly predictive of subsequent clinical recurrence.
  • Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late-stage cancer development programs across a range of cancer types.

ISHLT Elects New Board Members to Take Office in April 2022

Retrieved on: 
Wednesday, December 1, 2021
CCTC, Allied health professions, Marie Cassidy, Embryonic Stem Cell Research Oversight Committees, Doctor of Philosophy, Amyloidosis, MSN, Society, Risk, Board, Royal college, Lung transplantation, Heart transplantation, International Society, Nursing, Publication, MS, MRCP, Research, Patriots' Path Council, Lung, RN, Royal College of Surgeons in Ireland, Education, International Society for Heart and Lung Transplantation, Director, Transplant, Transfusion-related acute lung injury, FRCS, Multimedia, FNP, Patient, MCS, Executive, Thorax, Health, Organization, Royal Papworth Hospital, Management, Medicine, Medical device, Dentistry

The Society will welcome six members of the Board of Directors at the 42nd Annual ISHLT Annual Meeting & Scientific Sessions on 27-30 April, 2022.

Key Points: 
  • The Society will welcome six members of the Board of Directors at the 42nd Annual ISHLT Annual Meeting & Scientific Sessions on 27-30 April, 2022.
  • "The Governance and Executive Committees congratulate the newly elected officers and members of the board of directors," says Joseph G. Rogers, MD, Chair of the Governance Nominating Committee and ISHLT Past President.
  • He has served on the ISHLT Board of Directors since 2018 and is on the ISHLT Finance Committee, as Board liaison to the PATH Council, and on the Pulmonary AMR Working Group.
  • The officers and directors will take office on 30 April, 2022, at the conclusion of the ISHLT Annual Meeting.

Cancer Patients May Get Faster and More Personalized Treatment as Result of Collaboration Between GE Healthcare, University of Cambridge and Addenbrooke’s Hospital

Retrieved on: 
Monday, November 29, 2021
Technology, Medical Devices, Surgery, Hospitals, Other Technology, Managed Care, Health, Science, Oncology, Other Science, Newton, Patient, Ovarian cancer, News, University, Heart, CUH, Health information management, Cambridge Biomedical Campus, GE Healthcare, Technology, Disease, Surgeon, NYSE, Social, Cambridge Institute for Sustainability Leadership, Diagnosis, Rosie Hospital, Cancer, Cambridge Centre, Department of Oncology, University of Cambridge, University of Cambridge, Breast, Cancer Research UK, Student, NIHR, Education, AstraZeneca, Department, MDT, CBC, Thomas Edison, Information system, Humanities, Twitter, College, Cambridge University Hospitals NHS Foundation Trust, Research, Radiology, Health, Cambridge University Health Partners, Patent, Royal Papworth Hospital, EHR, Science, Learning, Cancer research, Medicine, Engineering, Ecosystem, LinkedIn, RIS, Marie Cassidy, Medical imaging, Pharmaceutical industry, Industrial design, Sales, GE Healthcare, The University of Cambridge, Cambridge University Hospitals, GE HEALTHCARE, THE UNIVERSITY OF CAMBRIDGE, CAMBRIDGE UNIVERSITY HOSPITALS

Thanks to ever-improving technologies, we now generate increasing amounts of complex data for each patient with cancer.

Key Points: 
  • Thanks to ever-improving technologies, we now generate increasing amounts of complex data for each patient with cancer.
  • The application is expected to be evaluated for ovarian cancer initially in Cambridge and the goal is to evaluate it across the UK, and beyond.
  • If the application is successfully developed, our vision is for it to be expanded for use in breast and kidney cancer patients.
  • CUH is a leading national centre for specialist treatment for rare or complex conditions and a university teaching hospital with a worldwide reputation.

Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting

Retrieved on: 
Wednesday, September 8, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials

The trial explored the effect of CMS I-neb on the frequency of pulmonary exacerbations in NCFB patients chronically infected with P. aeruginosa.

Key Points: 
  • The trial explored the effect of CMS I-neb on the frequency of pulmonary exacerbations in NCFB patients chronically infected with P. aeruginosa.
  • A total of 377 patients were randomized, 177 to CMS I-neb and 200 to placebo.
  • The annual rate of exacerbations was significantly lower in patients receiving CMS I-neb vs placebo (0.58 per patient per year vs 0.95, rate ratio (RR) 0.61 95% CI 0.46-0.82, p=0.00101).
  • These results are encouraging for patients as there is currently no approved drug treatment for this indication.